focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Grwth 3 Regulatory News (MIG3)

Share Price Information for Maven Grwth 3 (MIG3)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.00
Bid: 47.00
Ask: 49.00
Change: 0.00 (0.00%)
Spread: 2.00 (4.255%)
Open: 48.00
High: 48.00
Low: 48.00
Prev. Close: 48.00
MIG3 Live PriceLast checked at -
Maven Income and Growth VCT 3 is an Investment Trust

To achieve long-term capital appreciation and generate income for Shareholders by investing in a diversified portfolio of securities in smaller, unquoted UK companies and AIM/NEX quoted companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting

20 Oct 2021 16:46

RNS Number : 7206P
Maven Income and Growth VCT 3 PLC
20 October 2021
 

 

 

Maven Income and Growth VCT 3 PLC (the Company)

 

Result of General Meeting - 20 October 2021

This Announcement is made by the Company in connection with the offer for subscription (Offer) of new ordinary shares of 10p each in the capital of the Company (New Shares).

The Board is pleased to announce that, at the General Meeting of the Company held on 20 October 2021, the resolutions proposed, as set out in the Notice of General Meeting in the Circular to Shareholders dated 20 September 2021, were duly passed on a poll as follows:

Resolution 1 - to authorise the Directors to allot New Shares;

Resolution 2 - to approve the IMA Deed of Variation;

Resolution 3 - to authorise the disapplication of pre-emption rights;

Resolution 4 - to approve the cancellation of the share premium account; and

Resolution 5 - to approve the cancellation of the capital redemption reserve.

At the record date for the General Meeting, being 18 October 2021, the total number of voting rights in the Company stood at 79,151,967 and the total number of ordinary shares in issue was 79,151,967.

 

The Company advises that, for the General Meeting, valid proxy appointments were made in respect of

4,338,028 ordinary shares and that the number of proxy votes lodged for each Resolution were as follows:

 

Resolution

For

Discretion

Against

Withheld

Total

1

3,732,586

171,875

433,567

0

4,338,028

2*

2,092,351

178,348

649,333

1,417,996

4,338,028

3

 3,684,329

171,875

471,524

10,300

4,338,028

4

4,113,462

171,875

23,279

29,412

4,338,028

5

4,111,802

171,875

24,939

29,412

4,338,028

 

A vote withheld is not a vote in law and any such votes have not been included in the votes for or against the respective Resolutions.

 

\* The Board acknowledges that a small number of significant Shareholders have voted against Resolution 2 but would emphasise that, as stated in the Circular dated 20 September 2021, the Directors believe that it is in the best interests of the Company to remove the cap on any performance fee payable to Maven Capital Partners UK LLP (Maven) as it will incentivise and reward Maven appropriately when an exceptional return is achieved, and only when the Shareholders of the Company have also derived a significant benefit. The removal of this cap will also align the Company with the approach taken by the VCT sector in general, where such incentive payments are not subject to a monetary limit.

 

Passing of Resolutions

 

A copy of the Resolutions passed at the General Meeting held on 20 October 2021 have been submitted to the National Storage Mechanism and will shortly be available for inspection at:

 

https://www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism

 

Issued on behalf of the Board

 

Maven Capital Partners UK LLP

Secretary

 

20 October 2021

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMFLFSEIFLIFIL
Date   Source Headline
8th Feb 20239:43 amRNSIssue of Equity
1st Feb 20233:23 pmRNSUnaudited NAV and Proposed Final Dividend
12th Dec 20223:41 pmRNSDirectorate Change
12th Dec 20223:34 pmRNSStatement re Director's Other Quoted Directorships
9th Nov 20223:00 pmRNSResult of General Meeting
4th Nov 20222:35 pmRNSTransaction in Own Shares
31st Oct 20223:54 pmRNSTransaction in Own Shares
21st Oct 20222:45 pmRNSNet Asset Value(s)
7th Oct 20224:28 pmRNSPublication of a Prospectus
4th Oct 20223:30 pmRNSChange of Auditor
26th Aug 202210:04 amRNSIssue of Equity
22nd Aug 20229:33 amRNSStatement re Dividend Investment Scheme
29th Jul 202211:25 amRNSHalf-year Report
21st Jul 20224:38 pmRNSTransaction in Own Shares
13th Jul 202211:19 amRNSNet Asset Value and Interim Dividend
8th Jul 20223:28 pmRNSStatement re Joint Offers for Subscription
6th Jun 20222:15 pmRNSIssue of Equity
26th May 20225:02 pmRNSTransaction in Own Shares
26th Apr 202212:34 pmRNSIssue of Supplementary Prospectus
26th Apr 202210:51 amRNSIssue of Equity - Dividend Investment Scheme
21st Apr 20222:39 pmRNSStatement re Dividend Investment Scheme
6th Apr 20224:02 pmRNSNet Asset Value(s)
6th Apr 20221:45 pmRNSResult of AGM
5th Apr 20226:30 pmRNSIssue of Equity
23rd Mar 20225:10 pmRNSDirector/PDMR Shareholding
23rd Mar 20225:05 pmRNSIssue of Equity
21st Mar 20222:59 pmRNSPublication of Suppl.Prospcts
11th Mar 202211:35 amRNSIssue of Equity - Dividend Investment Scheme
10th Mar 202211:30 amRNSIssue of Equity
10th Mar 202211:20 amRNSStatement re Dividend Investment Scheme
7th Mar 20226:32 pmRNSAnnual Financial Report
22nd Feb 20222:27 pmRNSTransaction in Own Shares
18th Feb 20225:48 pmRNSIssue of Equity - Replacement Announcement
7th Feb 20221:53 pmRNSDirector/PDMR Shareholding
7th Feb 20221:52 pmRNSDirector/PDMR Shareholding
7th Feb 20221:50 pmRNSDirector/PDMR Shareholding
7th Feb 20221:48 pmRNSDirector/PDMR Shareholding
7th Feb 20221:47 pmRNSDirector/PDMR Shareholding
7th Feb 20221:46 pmRNSDirector/PDMR Shareholding
7th Feb 202210:50 amRNSIssue of Equity
4th Feb 20229:45 amRNSStatement re NAV and Final Dividend
31st Jan 20224:25 pmRNSStatement re Offer for Subscription
10th Jan 202212:43 pmRNSStatement re Offer for Subscription
5th Jan 202210:35 amRNSDividend Declaration
24th Nov 20214:45 pmRNSTransaction in Own Shares
29th Oct 202112:44 pmRNSNet Asset Value(s)
20th Oct 20214:46 pmRNSResult of General Meeting
20th Sep 20215:21 pmRNSPublication of a Prospectus
20th Sep 20214:57 pmRNSStatement re Change of Registrar
10th Sep 202112:34 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.